Dexcom (DXCM) Q4 2018 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2018 earnings summary
4 Nov, 2026Executive summary
FY18 revenue topped $1B for the first time, rising 44% YoY to $1,031.6M; U.S. revenue grew 37% and international revenue 74%.
G6 approval and launch, broader access efforts, and expanded manufacturing capacity supported growth; early G6 rollout also created operational challenges.
Financial highlights
FY18 gross profit was $663.9M, up from $492.1M; gross margin fell to 64% from 68%, reflecting channel and product mix, launches, and international expansion.
FY18 operating loss was $186.3M versus $42.5M; net loss was $127.1M versus $50.2M, and basic and diluted loss per share was $1.44 versus $0.58.
Q4 revenue was $338.0M and gross profit $222.8M; net loss was $179.7M, including the $217.7M Verily collaboration charge.
FY18 operating cash flow was $123.2M; cash, cash equivalents, and short-term marketable securities totaled $1,385.6M at year-end.
Outlook and guidance
Expanded Mesa manufacturing capacity was positioned to support broader G6 rollout, Medicare access targeted for late 2019, and preparation for G7, a fully disposable real-time CGM.
Growth opportunities include non-intensive Type 2 diabetes, gestational diabetes, and hospital monitoring; CGM penetration was viewed as low with substantial potential ahead.
Existing cash, projected commercial cash flows, and $195.6M available under the revolving credit facility were expected to cover liquidity needs for at least 12 months.
Latest events from Dexcom
- Revenue growth and margin gains were offset by lower earnings and a major Verily charge.DXCM
Q4 2021 - Revenue grew 19% as G7 clearance and expanded CGM access strengthened growth prospects.DXCM
Q4 2022 - Revenue climbed 43% as profitability arrived and G6 capacity doubled.DXCM
Q4 2019 - 31% revenue growth and 66% gross margin, with earnings lifted by a major tax benefit.DXCM
Q4 2020 - Q3 revenue and margins grew, lifting FY2026 guidance and supporting a new $1B buyback.DXCM
Q3 2026 - Q4 revenue grew 26% organically as FDA submissions and G7 integrations advanced.DXCM
Q4 2023 - CONNECT data, expanded coverage, and product innovation set stage for accelerated growth.DXCM
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue rose 13%, net income 39%, margins and guidance up, $600M shares repurchased.DXCM
Q2 2026 - Q3 2024 saw 2–3% revenue growth, strong international gains, and a $750M share repurchase.DXCM
Q3 2024